Long QT syndrome revisited.

Area of Science:

• Cardiology
• Genetics
• Pharmacology

Background:

• Congenital Long QT Syndrome (cLQTS) is an inherited cardiac disorder affecting children and adolescents.
• It presents with structurally normal hearts but carries a high risk of sudden cardiac death (SCD) if untreated.
• Over 300 mutations in 7 LQT genes are known.

Purpose of the Study:

• To review the current understanding and management of Congenital Long QT Syndrome (cLQTS).
• To highlight diagnostic approaches, treatment strategies, and emerging therapies.
• To address challenges in managing asymptomatic family members and acquired LQTS.

Main Methods:

• Review of existing literature on cLQTS diagnosis, genetics, and treatment.
• Analysis of current therapeutic mainstays like beta blockers and implantable cardioverter-defibrillators (ICDs).
• Discussion of the role of molecular genetic testing and preliminary gene-based therapies.

Main Results:

• Diagnosis relies on ECG, clinical presentation, and family history.
• Beta blockers are the primary treatment; ICDs are effective for high-risk patients in reducing SCD.
• Molecular genetic testing is valuable for family screening but remains largely a research tool.

Conclusions:

• Effective management of cLQTS involves risk stratification and established therapies.
• Further research is needed for gene-based therapies and optimal care for asymptomatic relatives.
• Physicians must be aware of drug interactions that can cause acquired LQTS by inhibiting the Ikr current.